Table 2.

Outcomes and disease response

Patient no.Follow-up: safety, moChange in EDSS from baseline, moOligoclonal bands, before/after HDIT (mo of f/u)
136122436Outcomes
1 47 0 0 0 0 +0.5 0 +/− (24)
2 45 0 NT −2.5 −3.0 0 NT −/− (24)
3 40 0 0 −0.5 −0.5 0 0 −/− (24)
4 38 +0.5 +1.0 −0.5 −0.5 −0.5 −0.5 −/− (12) Flare of MS with stem cell mobilization
5 34 0 0 0 0 0 +/+ (12)
6* 33 +0.5 +1.5 +0.5 +1.5 NT +/− (12) Progression of MS
7* 33 0 +0.5 +1.0 +1.0 +2.0 +/+ (12) Progression of MS
8 30 −0.5 0 NT NT NT −/− (3)
9 2 EBV-PTLD; died on day +53
10 29 0 0 0 0 0 +/+ (12)
11 29 0 0 0 +0.5 0 +/+ (12) ITP; at day 60
12* 29 0 0 0 0 +1.0 +/+ (12) Progression of MS
13 28 −0.5 0 0 0 +0.5 −/− (12) Hypothyroidism
14* 28 0 −0.5 0 +0.5 +1.0 +/+ (12) Neuropathy/hypothermia, at month 17; progression of MS
15 27 +0.5 0 +0.5 +0.5 0 −/− (12) Brachial neuritis, at day 30
16* 23 +1.0 +1.0 +1.0 +1.0 NT −/+ (3) Progression of MS; died at month 23
17 27 +0.5 0 NT 0 +0.5 +/NE (3)
18 26 0 −0.5 −0.5 0 0 +/+ (3)
19 26 +1.5 0 −0.5 −0.5 +0.5 +/+ (12)
20 24 −0.5 −0.5 −0.5 −0.5 0 +/+ (12)
21 23 −0.5 −1.0 −0.5 0 0 +/− (12)
22 22 0 0 −0.5 −0.5 NT
23 18 NT 0 +0.5 0 NT
24* 18 0 +1.0 +1.0 +1.0 −/− (3) Progression of MS
25 17 0 0 NT NT +/NT
26 15 0 0 0 0 −/− (3)
  • Neurologic assessment and scoring of EDSS was done at scheduled visits at 1, 3, 6, 12, 24, and 36 months. MRI results are changes from baseline at last scheduled study. mo indicates month; f/u, follow-up; NT, not tested; —, no data; and NE, not evaluable.

  • * Determined to have progressed.

  • Lost to follow-up.